Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art

Pharmacology and Therapeutics

Volumn 161, Issue , 2016, Pages 1-10

  Marcsisin, Sean R ^a   Reichard, Gregory ^a   Pybus, Brandon S ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b EISENHOWER ARMY MEDICAL CENTER   (United States)

Author keywords

8 Aminoquinoline; CYP 2D6; Hepatic metabolism; Pharmacogenomics; Plasmodium vivax; Primaquine

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; CYTOCHROME P450 2D6; PRIMAQUINE; ANTIMALARIAL AGENT; PRODRUG;

DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; ELIMINATION HALF-LIFE; ENZYME METABOLISM; GENETIC VARIATION; HUMAN; MALARIA; METABOLIC ACTIVATION; METABOLOMICS; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; RELAPSE; REVIEW; ANIMAL; DRUG INTERACTION; GENETIC POLYMORPHISM; GENETICS; METABOLISM;

ANIMALS; ANTIMALARIALS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; HUMANS; METABOLOMICS; POLYMORPHISM, GENETIC; PRIMAQUINE; PRODRUGS;

EID: 84962708747     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.03.011     Document Type: Review

References (79)

1. R. Allahyari, A. Strother, I.M. Fraser, and A.J. Verbiscar Synthesis of certain hydroxy analogues of the antimalarial drug primaquine and their in vitro methemoglobin-producing and glutathione-depleting activity in human erythrocytes J Med Chem 27 1984 407 410
2. G. Alvarez, J.G. Pineros, A. Tobon, A. Rios, A. Maestre, S. Blair, and et al. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia AmJTrop Med Hyg 75 2006 605 609
3. A.S. Alving Study of pentaquine and isopentaquine, therapeutic agents effective in reducing relapse rate in vivax malaria Abstr Int Congr Trop Med Malar 56 1948 58
4. A.S. Alving, J. Arnold, R.S. Hockwald, C.B. Clayman, R.J. Dern, E. Beutler, and et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine J Lab Clin Med 46 1955 301 306
5. A.S. Alving, B. Craige, T.N. Pullman, C.M. Whorton, R. Jones, and L. Eichelberger Procedures used at Stateville Penitentiary for the testing of potential antimalarial agents J Clin Invest 27 1948 2 5
6. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 1999 361 398
7. E.A. Ashley, J. Recht, and N.J. White Primaquine: The risks and the benefits Malar J 13 2014 418
8. S. Asimus, D. Elsherbiny, T.N. Hai, B. Jansson, N.V. Huong, M.G. Petzold, and et al. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects Fundam Clin Pharmacol 21 2007 307 316
9. R.K. Bains African variation at cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases Evol Med Public Health 2013 2013 118 134
10. K.P. Bateman, J. Castro-Perez, M. Wrona, J.P. Shockcor, K. Yu, R. Oballa, and et al. MSE with mass defect filtering for in vitro and in vivo metabolite identification Rapid Commun Mass Spectrom 21 2007 1485 1496
11. J.W. Bennett, B.S. Pybus, A. Yadava, D. Tosh, J.C. Sousa, W.F. McCarthy, and et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria N Engl J Med 369 2013 1381 1382
12. L.J. Bolchoz, R.A. Budinsky, D.C. McMillan, and D.J. Jollow Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline J Pharmacol Exp Ther 297 2001 509 515
13. Z.S. Bowman, J.E. Oatis Jr., J.L. Whelan, D.J. Jollow, and D.C. McMillan Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine J Pharmacol Exp Ther 309 2004 79 85
14. M.D. Cappellini, and G. Fiorelli Glucose-6-phosphate dehydrogenase deficiency Lancet 371 2008 64 74
15. C.B. Clayman, J. Arnold, R.S. Hockwald, E.H. Yount Jr., J.H. Edgcomb, and A.S. Alving Toxicity of primaquine in Caucasians J Am Med Assoc 149 1952 1563 1568
16. G.R. Coatney, A.S. Alving, R. Jones Jr., D.D. Hankey, D.H. Robinson, P.L. Garrison, and et al. Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency AmJTrop Med Hyg 2 1953 985 988
17. K.R. Crews, A. Gaedigk, H.M. Dunnenberger, T.E. Klein, D.D. Shen, J.T. Callaghan, and et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype Clin Pharmacol Ther 91 2012 321 326
18. K.R. Crews, A. Gaedigk, H.M. Dunnenberger, J.S. Leeder, T.E. Klein, K.E. Caudle, and et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update Clin Pharmacol Ther 95 2014 376 382
19. G.A. Deye, and A.J. Magill Primaquine for prophylaxis of malaria: Has the CYP sailed? J Travel Med 21 2014 67 69
20. A. Di Lorenzo, R.L. Marx, A.S. Alving, and R. Jones Jr. Korean vivax malaria. IV. curative effect of 15 milligrams of primaquine daily for 7 days AmJTrop Med Hyg 2 1953 983 984
21. J.H. Edgcomb, J. Arnold, E.H. Yount Jr., A.S. Alving, L. Eichelberger, G.M. Jeffery, and et al. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report J Natl Malar Soc 9 1950 285 292
22. M. Eichelbaum, M.P. Baur, H.J. Dengler, B.O. Osikowska-Evers, G. Tieves, C. Zekorn, and et al. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22 Br J Clin Pharmacol 23 1987 455 458
23. M. Eichelbaum, N. Spannbrucker, B. Steincke, and H.J. Dengler Defective N-oxidation of sparteine in man: A new pharmacogenetic defect Eur J Clin Pharmacol 16 1979 183 187
24. R.C. Elderfield, S.J. Gensler, and et al. Alkylaminoalkyl derivatives of 8-aminoquinoline J Am Chem Soc 68 1946 1524 1529
25. P.S. Fasinu, B.L. Tekwani, N.P. Nanayakkara, B. Avula, H.M. Herath, Y.H. Wang, and et al. Enantioselective metabolism of primaquine by human CYP2D6 Malar J 13 2014 507
26. K.A. Fletcher, D.A. Evans, H.M. Gilles, J. Greaves, D. Bunnag, and T. Harinasuta Studies on the pharmacokinetics of primaquine Bull World Health Organ 59 1981 407 412
27. P.S. Fasinu, B. Avula, B.L. Tekwani, N.P. Nanayakkara, Y.H. Wang, and H.M. Bandera Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes Malar J 2016 http://dx.doi.org/0.1186/s12936-016-1270-1 (in press)
28. T. Furuya, J.M. Sa, C.E. Chitnis, T.E. Wellems, and T.T. Stedman Reticulocytes from cryopreserved erythroblasts support Plasmodium vivax infection in vitro Parasitol Int 63 2014 278 284
29. S. Ganesan, B.L. Tekwani, R. Sahu, L.M. Tripathi, and L.A. Walker Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes Toxicol Appl Pharmacol 241 2009 14 22
30. A. Garg, B. Prasad, H. Takwani, M. Jain, R. Jain, and S. Singh Evidence of the formation of direct covalent adducts of primaquine, 2-tert-butylprimaquine (NP-96) and monohydroxy metabolite of NP-96 with glutathione and N-acetylcysteine J Chromatogr B Analyt Technol Biomed Life Sci 879 2011 1 7
31. P.L. Garrison, D.D. Hankey, W.G. Coker, W.N. Donovan, B. Jastremski, G.R. Coatney, and et al. Cure of Korean vivax malaria with pamaquine and primaquine J Am Med Assoc 149 1952 1562 1563
32. F.J. Gonzalez, F. Vilbois, J.P. Hardwick, O.W. McBride, D.W. Nebert, H.V. Gelboin, and et al. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22 Genomics 2 1988 174 179
33. P.M. Graves, H. Gelband, and P. Garner Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission Cochrane Database Syst Rev 2 2015 CD008152
34. F.P. Guengerich Mechanisms of cytochrome P450 substrate oxidation: Minireview J Biochem Mol Toxicol 21 2007 163 168
35. B. Hanboonkunupakarn, E.A. Ashley, P. Jittamala, J. Tarning, S. Pukrittayakamee, W. Hanpithakpong, and et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects Antimicrob Agents Chemother 58 2014 7340 7346
36. R. Hayeshi, C. Masimirembwa, S. Mukanganyama, and A.L. Ungell The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux Eur J Pharm Sci 29 2006 70 81
37. R.S. Hockwald, J. Arnold, C.B. Clayman, and A.S. Alving Toxicity of primaquine in Negroes J Am Med Assoc 149 1952 1568 1570
38. Y.L. Hong, H.Z. Pan, M.D. Scott, and S.R. Meshnick Activated oxygen generation by a primaquine metabolite: Inhibition by antioxidants derived from Chinese herbal remedies Free Radic Biol Med 12 1992 213 218
39. M. Ingelman-Sundberg Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J 5 2005 6 13
40. R.J. Ingram, C. Crenna-Darusallam, S. Soebianto, R. Noviyanti, and J.K. Baird The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea Malar J 13 2014 488
41. X. Jin, T.L. Luong, N. Reese, H. Gaona, V. Collazo-Velez, C. Vuong, and et al. Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations J Pharmacol Toxicol Methods 70 2014 188 194
42. P. Jittamala, S. Pukrittayakamee, E.A. Ashley, F. Nosten, B. Hanboonkunupakarn, S.J. Lee, and et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects Antimicrob Agents Chemother 59 2015 505 513
43. R. Jones Jr., L.S. Jackson, A. Di Lorenzo, R.L. Marx, B.L. Levy, E.C. Kenny, and et al. Korean vivax malaria. III. Curative effect and toxicity of primaquine in doses from 10 to 30 mg. daily AmJTrop Med Hyg 2 1953 977 982
44. M. Kitada Genetic polymorphism of cytochrome P450 enzymes in Asian populations: Focus on CYP2D6 Int J Clin Pharmacol Res 23 2003 31 35
45. W.A. Krotoski, D.M. Krotoski, P.C. Garnham, R.S. Bray, R. Killick-Kendrick, C.C. Draper, and et al. Relapses in primate malaria: discovery of two populations of exoerythrocytic stages. Preliminary note Br Med J 280 1980 153 154
46. S. Kumar, R. Sharma, and A. Roychowdhury Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: A medicinal chemistry perspective Curr Med Chem 19 2012 3605 3621
47. D.L. Lancaster, R.A. Adio, K.K. Tai, O.O. Simooya, G.D. Broadhead, G.T. Tucker, and et al. Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs J Pharm Pharmacol 42 1990 267 271
48. A. Mahgoub, J.R. Idle, L.G. Dring, R. Lancaster, and R.L. Smith Polymorphic hydroxylation of debrisoquine in man Lancet 2 1977 584 586
49. S.R. Marcsisin, J.C. Sousa, G.A. Reichard, D. Caridha, Q. Zeng, N. Roncal, and et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: Implications for the 8-aminoquinoline class of anti-malarial compounds Malar J 13 2014 2
50. M.B. Markus Do hypnozoites cause relapse in malaria? Trends Parasitol 31 2015 239 245
51. J.D. McChesney, and S. Sarangan Rapid aromatic hydrogen exchange in the antimalarial primaquine Pharm Res 1 1984 184 186
52. U.A. Meyer, and U.M. Zanger Molecular mechanisms of genetic polymorphisms of drug metabolism Annu Rev Pharmacol Toxicol 37 1997 269 296
53. G.W. Mihaly, S.A. Ward, G. Edwards, D.D. Nicholl, M.L. Orme, and A.M. Breckenridge Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size Br J Clin Pharmacol 19 1985 745 750
54. G.W. Mihaly, S.A. Ward, G. Edwards, M.L. Orme, and A.M. Breckenridge Pharmacokinetics of primaquine in man: Identification of the carboxylic acid derivative as a major plasma metabolite Br J Clin Pharmacol 17 1984 441 446
55. S. Morais Mda, and O. Augusto Peroxidation of the antimalarial drug primaquine: characterization of a benzidine-like metabolite with methaemoglobin-forming activity Xenobiotica 23 1993 133 139
56. C.A. Morris, R. Pokorny, L. Lopez-Lazaro, R.M. Miller, S. Arbe-Barnes, S. Duparc, and et al. Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol Antimicrob Agents Chemother 58 2014 5900 5908
57. E.J. Nelwan, L.L. Ekawati, B. Tjahjono, R. Setiabudy, I. Sutanto, K. Chand, and et al. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia BMC Med 13 2015 294
58. S. Ng, R.E. Schwartz, S. March, A. Galstian, N. Gural, J. Shan, and et al. Human iPSC-derived hepatocyte-like cells support Plasmodium liver-stage infection in vitro Stem Cell Reports 4 2015 348 359
59. B.M. Potter, L.H. Xie, C. Vuong, J. Zhang, P. Zhang, D. Duan, and et al. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics Antimicrob Agents Chemother 59 2015 2380 2387
60. R.N. Prasad, S.K. Garg, R.C. Mahajan, and N.K. Ganguly Pharmacokinetics of primaquine in rhesus monkeys Int J Clin Pharmacol Ther Toxicol 23 1985 45 46
61. S.C. Preissner, M.F. Hoffmann, R. Preissner, M. Dunkel, A. Gewiess, and S. Preissner Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy PLoS One 8 2013 e82562
62. S. Pukrittayakamee, J. Tarning, P. Jittamala, P. Charunwatthana, S. Lawpoolsri, S.J. Lee, and et al. Pharmacokinetic interactions between primaquine and chloroquine Antimicrob Agents Chemother 58 2014 3354 3359
63. B.S. Pybus, S.R. Marcsisin, X. Jin, G. Deye, J.C. Sousa, Q. Li, and et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6 Malar J 12 2013 212
64. B.S. Pybus, J.C. Sousa, X. Jin, J.A. Ferguson, R.E. Christian, R. Barnhart, and et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine Malar J 11 2012 259
65. R. Rochford, C. Ohrt, P.C. Baresel, B. Campo, A. Sampath, A.J. Magill, and et al. Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity Proc Natl Acad Sci U S A 110 2013 17486 17491
66. N. Scheer, Y. Kapelyukh, J. McEwan, V. Beuger, L.A. Stanley, A. Rode, and et al. Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines Mol Pharmacol 81 2012 63 72
67. D. Spaggiari, G. L., and S. Rudaz Coupling ultra-high-pressure liquid chromatography with mass spectrometry for in-vitro drug-metabolism studies TrAC Trends Anal Chem 63 2014 129 139
68. P.L. St Jean, Z. Xue, N. Carter, G.C. Koh, S. Duparc, M. Taylor, and et al. Tafenoquine treatment of Plasmodium vivax malaria: Suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the phase 2b DETECTIVE trial Malar J 15 2016 97
69. I. Sutanto, B. Tjahjono, H. Basri, W.R. Taylor, F.A. Putri, R.A. Meilia, and et al. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia Antimicrob Agents Chemother 57 2013 1128 1135
70. B.L. Tekwani, B. Avula, R. Sahu, N.D. Chaurasiya, S.I. Khan, S. Jain, and et al. Enantioselective pharmacokinetics of primaquine in healthy human volunteers Drug Metab Dispos 43 2015 571 577
71. N. Vale, R. Moreira, and P. Gomes Primaquine revisited six decades after its discovery Eur J Med Chem 44 2009 937 953
72. J. Vasquez-Vivar, and O. Augusto Hydroxylated metabolites of the antimalarial drug primaquine Oxidation and redox cycling J Biol Chem 267 1992 6848 6854
73. J. Vasquez-Vivar, and O. Augusto Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo Biochem Pharmacol 47 1994 309 316
74. C. Vuong, L.H. Xie, B.M. Potter, J. Zhang, P. Zhang, D. Duan, and et al. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics Antimicrob Agents Chemother 59 2015 3864 3869
75. S.A. Ward, G.W. Mihaly, G. Edwards, S. Looareesuwan, R.E. Phillips, P. Chanthavanich, and et al. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects Br J Clin Pharmacol 19 1985 751 755
76. J. Xuan, S. Chen, B. Ning, W.H. Tolleson, and L. Guo Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity Chem Biol Interact 2015
77. X. Yang, K. Atkinson, and L. Di Novel cytochrome P450 reaction phenotyping for low clearance compounds using hepatocyte relay method Drug Metab Dispos 2015
78. U.M. Zanger, and M. Schwab Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation Pharmacol Ther 138 2013 103 141
79. U.M. Zanger, S. Raimundo, and M. Eichelbaum Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry Naunyn Schmiedeberg's Arch Pharmacol 369 2004 23 37